Biogen

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors

Retrieved on: 
Tuesday, December 19, 2023
Atlas Venture, Therapeutic index, Atlas, Yale University, Cytokine, Science, Drug discovery, Medical school, Sutro Biopharma, Research, Chemistry, BeiGene, Tislelizumab, Acquisition, EGFR, File, Inflammation, Physician, Juno Therapeutics, MBA, College, Blinatumomab, Therapy, Columbia University, Lisocabtagene maraleucel, Cancer, University, Head, Feinberg School of Medicine, BMS, Harvard College, Surgeon, Medicine, Biogen, FACP, Pharmaceutical industry

GERMANTOWN, Md., Dec. 19, 2023 /PRNewswire/ -- Deka Biosciences ("Deka") today announced the appointments of Stanley Frankel, M.D., FACP, as senior clinical advisor, interim chief medical officer and scientific advisory board member, and Stuart Chaffee, Ph.D. as an independent director and chairman of the Board. Deka is a privately held biotech company developing next-generation cytokine therapies to treat cancer and inflammatory diseases based on a patient's individual immune response. Deka's lead asset, DK210 (EGFR), is currently being evaluated for the treatment of multiple solid tumors in a Phase 1 clinical trial.

Key Points: 
  • Deka is a privately held biotech company developing next-generation cytokine therapies to treat cancer and inflammatory diseases based on a patient's individual immune response.
  • Dr. Frankel joins Deka as a hematologist-oncologist with over 20 years of industry experience, including the research, clinical development, and commercialization of immuno-oncology and cellular therapies.
  • He is a non-executive director at Precision Biosciences and a member of the board of directors at Myeloid Therapeutics.
  • Earlier in his career, Dr. Chaffee served in several roles at Biogen across finance, business development, program leadership, and corporate strategy.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, CNS, Capsule, Woman, Tell, Medicaid, Behavior, Hope, Therapy, Breast milk, Grammatical mood, Physician, Risk, New America (organization), Patient, Multimedia, Insurance, Pregnancy, CIV, Theft, Medical research, Benzodiazepine, Vitamin, Diagnosis, BIIB, PPD, Mental health, Central nervous system, Alertness, Confusion, Walking, Somnolence, OBGYN, Dizziness, Pharmacy, Dietary supplement, Pharmaceutical industry, Nursing, Birth control, Liquor, Gasoline, Health insurance, Hospital, Sage, Biogen

View the full release here: https://www.businesswire.com/news/home/20231213368658/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025

Retrieved on: 
Tuesday, December 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NDA, CNS, Johnson & Johnson, AstraZeneca, Therapy, Pathology, Commercial, Risk, Disease, Patient, Nate Green (author), Marketing, Optimer ligand, MD, File, Janssen, Doctor of Philosophy, Market access, Central nervous system, APOE4, Nate, Pharmaceutical industry, Nursing, Alzheon, Biogen, Genentech

“Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.

Key Points: 
  • “Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.
  • He has more than 20 years of commercial launch, sales, market access, and leadership experience in the biopharmaceutical industry.
  • Previously, Mr. Greene held commercial and executive roles at Janssen, Otsuka, and Biogen, with over a dozen launches in CNS disorders and Alzheimer’s.
  • Having these strong leaders further enhances our ability to establish critical partnerships and patient advocacy programs to support a successful commercial launch in 2025.”

Gene Therapy Research Report 2023: Market Analysis by Gene Silencing, Gene Augmentation, Vector, Therapeutic Area, Delivery Method, RoA - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Biogen, Research, Conditional sentence, Oligonucleotide, Prevalence, Gilead Sciences, Retrovirus, Growth, Neurology, Bristol Myers Squibb, USD, Therapy, Novartis, Cancer, Region, Gene silencing, Government, AAV, Intravenous therapy, Pharmaceutical industry

The "Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the gene therapy market is driven by several key factors, including increasing initiatives in genomic research and a growing number of regulatory approvals for gene therapy products.
  • Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas..
  • Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

Retrieved on: 
Friday, December 8, 2023
Attention, Novo Nordisk, Research, Conditional sentence, AstraZeneca, Prevalence, Gene editing, Takeda Pharmaceutical Company, Proteomics, Gilead Sciences, Biotechnology, Sanofi, Bayer, Genomics, DSM-IV codes, Genetic engineering, BRD, Cas9, Inherited disorders of trafficking, Tissue engineering, GSK, Therapy, Novartis, Chronic condition, Eli Lilly and Company, Drug discovery, Cancer, GSK plc, Amgen, Growth, Pfizer, Bristol Myers Squibb, Hospital, Diabetes, Biogen, AbbVie, Drug development, Cabozantinib, Pharmaceutical industry, Generic drug, Fine chemical

Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.

Key Points: 
  • Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.
  • This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market .
  • The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market.
  • The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Advancing Diversity in Alzheimer's Disease (AD) Research: Innovative Strategies for Collaborative Solutions, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 15, 2023
Research, Roger Hawkins (drummer), Patient, Fusion Global Business Solutions, Education, Nursing, Alzheimer's disease, Biogen

TORONTO, Nov. 15, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into multifaceted strategies aimed at enhancing diversity within the realm of Alzheimer's disease (AD) research. Addressing significant challenges rooted in the widespread lack of trust within diverse patient populations, the featured speakers forge collaborative efforts with advocacy groups, who serve as crucial bridges between the healthcare system and the communities they serve. Going beyond conventional screening practices, these strategies also involve extensive examination of medical records and employ a diverse array of tactics to identify potential patients who might otherwise go unnoticed.

Key Points: 
  • Attendees will learn about the multifaceted strategy for promoting diversity within Alzheimer's disease clinical research, including the use of medical record examinations and diverse identification tactics.
  • TORONTO, Nov. 15, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into multifaceted strategies aimed at enhancing diversity within the realm of Alzheimer's disease (AD) research.
  • This webinar involves the open exchange of ideas, acknowledging that the path to solutions is neither instantaneous nor linear.
  • Join this webinar in shaping a future where diversity is the cornerstone of progress in Alzheimer's research.